Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?

Evaluation of the prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in a phase III randomized adjuvant breast cancer (BC) trial (BIG 2-98) of node-positive (N+) BC comparing the addition of docetaxel to doxorubicin (A-T) with doxorubicin (A)-only chemotherapy (CT).

(2017) S. Loi et al.   JOURNAL OF CLINICAL ONCOLOGY

CD73-Deficient Mice Are Resistant to Carcinogenesis

(2012) J. Stagg et al.   CANCER RESEARCH

Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients

(2012) Sebastiano Gangemi et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer

(2012) Holbrook E. Kohrt et al.   JOURNAL OF CLINICAL INVESTIGATION

Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled Analysis

(2012) Michail Ignatiadis et al.   JOURNAL OF CLINICAL ONCOLOGY

The immune score as a new possible approach for the classification of cancer

(2012) Jérôme Galon et al.   Journal of Translational Medicine

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

(2012) Hirokazu Matsushita et al.   NATURE

The secret ally: immunostimulation by anticancer drugs

(2012) Lorenzo Galluzzi et al.   NATURE REVIEWS DRUG DISCOVERY

CD73: a potent suppressor of antitumor immune responses

(2012) Paul. A. Beavis et al.   TRENDS IN IMMUNOLOGY

Natural Innate and Adaptive Immunity to Cancer

(2011) Matthew D. Vesely et al.   Annual Review of Immunology

Macrophage Binding to Receptor VCAM-1 Transmits Survival Signals in Breast Cancer Cells that Invade the Lungs

(2011) Qing Chen et al.   CANCER CELL

Suppression of T-cell responses by tumor metabolites

(2011) Katrin Singer et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors

(2011) S. R. Mattarollo et al.   CANCER RESEARCH

Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors

(2011) S. F. Ngiow et al.   CANCER RESEARCH

The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti-CTLA-4 Therapy

(2011) T. Fu et al.   CANCER RESEARCH

Anti-IL-23 Monoclonal Antibody Synergizes in Combination with Targeted Therapies or IL-2 to Suppress Tumor Growth and Metastases

(2011) M. W. L. Teng et al.   CANCER RESEARCH

Agonist Anti-CD137 mAb Act on Tumor Endothelial Cells to Enhance Recruitment of Activated T Lymphocytes

(2011) A. Palazon et al.   CANCER RESEARCH

CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis

(2011) J. Stagg et al.   CANCER RESEARCH

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

(2011) James S. Wilmott et al.   CLINICAL CANCER RESEARCH

CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice

(2011) Long Wang et al.   JOURNAL OF CLINICAL INVESTIGATION

Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction

(2011) Bernhard Mlecnik et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer

(2011) Sahar M.A. Mahmoud et al.   JOURNAL OF CLINICAL ONCOLOGY

Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer

(2011) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

Contribution of IL-17–producing γδ T cells to the efficacy of anticancer chemotherapy

(2011) Yuting Ma et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

(2011) J. Stagg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice

(2011) M. Michaud et al.   SCIENCE

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

TNF superfamily in inflammatory disease: translating basic insights

(2011) Michael Croft et al.   TRENDS IN IMMUNOLOGY

CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells

(2010) H. Narazaki et al.   BLOOD

Overall survival and PD-L1 expression in metastasized malignant melanoma

(2010) Jules Gadiot et al.   CANCER

The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity

(2010) SaeGwang Park et al.   CANCER CELL

CD73 on Tumor Cells Impairs Antitumor T-Cell Responses: A Novel Mechanism of Tumor-Induced Immune Suppression

(2010) D. Jin et al.   CANCER RESEARCH

Tumor Antigen–Targeted, Monoclonal Antibody–Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape

(2010) Robert L. Ferris et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

(2010) Kaori Sakuishi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Extracellular adenosine triphosphate and adenosine in cancer

(2010) J Stagg et al.   ONCOGENE

Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis

(2010) J. Stagg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CD4+ T Cells Regulate Pulmonary Metastasis of Mammary Carcinomas by Enhancing Protumor Properties of Macrophages

(2009) David G. DeNardo et al.   CANCER CELL

Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

(2009) Q. Gao et al.   CLINICAL CANCER RESEARCH

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

(2009) Carsten Denkert et al.   JOURNAL OF CLINICAL ONCOLOGY

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors

(2009) François Ghiringhelli et al.   NATURE MEDICINE

The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer

(2008) M. Schmidt et al.   CANCER RESEARCH

Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

(2008) C. Desmedt et al.   CLINICAL CANCER RESEARCH

OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection

(2008) Silvia Piconese et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Stromal gene expression predicts clinical outcome in breast cancer

(2008) Greg Finak et al.   NATURE MEDICINE